Created: | 2002-03-18 |
Last modified: | 2020-06-05 |
Find Related PDB Entry |
---|
Find related ligands: |
---|
Chemical Details | |
---|---|
Formal Charge | 0 |
Atom Count | 51 |
Chiral Atom Count | 5 |
Bond Count | 51 |
Aromatic Bond Count | 0 |
Chemical Component Summary | |
---|---|
Name | 3-(1-ACETYLAMINO-2-ETHYL-BUTYL)-4-GUANIDINO-2-HYDROXY-CYCLOPENTANECARBOXYLIC ACID |
Synonyms | BCX-1812 |
Systematic Name (OpenEye OEToolkits) | (1S,2S,3R,4R)-3-[(1S)-1-acetamido-2-ethyl-butyl]-4-carbamimidamido-2-hydroxy-cyclopentane-1-carboxylic acid |
Formula | C15 H28 N4 O4 |
Molecular Weight | 328.407 |
Type | NON-POLYMER |
Chemical Descriptors | |||
---|---|---|---|
Type | Program | Version | Descriptor |
SMILES | ACDLabs | 10.04 | O=C(O)C1CC(NC(=[N@H])N)C(C(NC(=O)C)C(CC)CC)C1O |
SMILES | CACTVS | 3.341 | CCC(CC)[CH](NC(C)=O)[CH]1[CH](O)[CH](C[CH]1NC(N)=N)C(O)=O |
SMILES | OpenEye OEToolkits | 1.5.0 | CCC(CC)C(C1C(CC(C1O)C(=O)O)NC(=N)N)NC(=O)C |
Canonical SMILES | CACTVS | 3.341 | CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@H](C[C@H]1NC(N)=N)C(O)=O |
Canonical SMILES | OpenEye OEToolkits | 1.5.0 | CCC(CC)[C@@H]([C@H]1[C@@H](C[C@@H]([C@H]1O)C(=O)O)NC(=N)N)NC(=O)C |
InChI | InChI | 1.03 | InChI=1S/C15H28N4O4/c1-4-8(5-2)12(18-7(3)20)11-10(19-15(16)17)6-9(13(11)21)14(22)23/h8-13,21H,4-6H2,1-3H3,(H,18,20)(H,22,23)(H4,16,17,19)/t9-,10+,11+,12-,13+/m0/s1 |
InChIKey | InChI | 1.03 | XRQDFNLINLXZLB-CKIKVBCHSA-N |
DrugBank ID | DB06614 |
---|---|
Name | Peramivir |
Groups |
|
Description | Peramivir is an antiviral agent developed by Biocryst Pharmaceuticals to treat influenza A/B. The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic. Being an influenza virus neuraminidase inhibitor, peramivir works by preventing new viruses from emerging from infected cells. Due to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. The injectable intravenous formulation of peramivir was approved by the FDA in September 2017 for the treatment of acute uncomplicated influenza to pediatric patients 2 years and older who have been symptomatic for no more than two days. |
Synonyms |
|
Brand Names |
|
Indication | Peramivir is indicated for the treatment of acute uncomplicated influenza in patients six months and older who have been symptomatic for no more than two days.[L36768] |
Categories |
|
ATC-Code | J05AH03 |
CAS number | 330600-85-6 |
Name | Target Sequence | Pharmacological Action | Actions |
---|---|---|---|
Neuraminidase | MNPNQKILCTSATALVIGTIAVLIGITNLGLNIGLHLKPSCNCSHSQPEA... | unknown | inhibitor |
Neuraminidase | MNPNQKIITIGSVSLTIATICFLMQIAILVTTVTLHFKQYECSSPPNNQV... | unknown | inhibitor |
Neuraminidase | MLPSTIQTLTLFLTSGGVLLSLYVSASLSYLLYSDILLKFSSKITAPTMT... | unknown | inhibitor |
Resource Name | Reference |
---|---|
PubChem | 154234,86310107 |
ChEMBL | CHEMBL139367 |
ChEBI | CHEBI:85202 |
RCSB PDB Core Operations are funded by theU.S. National Science Foundation (DBI-2321666), theUS Department of Energy (DE-SC0019749), and theNational Cancer Institute,National Institute of Allergy and Infectious Diseases, andNational Institute of General Medical Sciences of theNational Institutes of Health under grant R01GM157729.